Literature DB >> 2787338

Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study.

A F Finzi1, N Mozzanica, A Cattaneo, G Chiappino, P D Pigatto.   

Abstract

The effectiveness of low doses of cyclosporine (3 to 5 mg/kg/day) for short-term treatment in 13 patients with severe psoriasis was studied. The psoriasis cleared in 12 of 13 patients within 3 to 4 weeks of treatment, and there was appreciable improvement in the thirteenth patient. No major side effects were observed: two patients showed biochemical evidence of slight transient renal dysfunction and three others had cutaneous infections (two viral and one mycotic). An immunohistologic study showed that the psoriatic plaques contained an infiltrate composed mainly of activated helper T lymphocytes. After 15 days of cyclosporine treatment, CD4+ cells were significantly fewer in the epidermis and dermis, and Langerhans cells were more regularly distributed in the epidermis. Our studies of neutrophil chemotaxis showed that it is not significantly influenced by cyclosporine in vitro but is decreased in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787338     DOI: 10.1016/s0190-9622(89)70154-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Changes in numbers of epidermal cell adhesion molecules caused by oral cyclosporin in psoriasis.

Authors:  B D Edwards; S M Andrew; J B O'Driscoll; R J Chalmers; F W Ballardie; A J Freemont
Journal:  J Clin Pathol       Date:  1993-08       Impact factor: 3.411

Review 2.  German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

Authors:  A Nast; I Kopp; M Augustin; K B Banditt; W H Boehncke; M Follmann; M Friedrich; M Huber; C Kahl; J Klaus; J Koza; I Kreiselmaier; J Mohr; U Mrowietz; H M Ockenfels; H D Orzechowski; J Prinz; K Reich; T Rosenbach; S Rosumeck; M Schlaeger; G Schmid-Ott; M Sebastian; V Streit; T Weberschock; B Rzany
Journal:  Arch Dermatol Res       Date:  2007-05-12       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.